Last $1.92 USD
Change Today -0.06 / -3.03%
Volume 42.3K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 1:22 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$1.98
Previous Close
$1.98
Day High
$1.98
Day Low
$1.90
52 Week High
10/2/13 - $10.56
52 Week Low
08/4/14 - $1.90
Market Cap
18.1M
Average Volume 10 Days
76.8K
EPS TTM
$-2.28
Shares Outstanding
9.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology in the United States and internationally. The company’s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melphalan hepatic delivery system that administers concentrated regional chemotherapy to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

37 Employees
Last Reported Date: 03/12/14
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Interim Chief Executive Officer, Interim Pres...
Total Annual Compensation: $309.6K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $330.2K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $245.6K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $199.2K
Consultant
Total Annual Compensation: $333.6K
Compensation as of Fiscal Year 2013.

delcath systems inc (DCTH) Key Developments

Delcath Systems, Inc. Announces Management Changes

Delcath Systems, Inc. announced the reorganization of the company's leadership as Dr. Jennifer Simpson has been appointed interim President and interim CEO. Dr. Simpson has served as interim Co-President and interim Co-CEO of Delcath since September 2013. Dr. Graham Miao, who has served as interim Co-President, interim Co-CEO and CFO will be leaving the company at the end of September 2014 to pursue other opportunities. Barbra Keck, currently Vice President, Controller & Principal Accounting Officer will assume the responsibilities of Principal Financial Officer. In addition, Dr. Roger G. Stoll, who has been a member of the Delcath Board of Directors since 2008, has been appointed to the newly created position of Executive Chairman. He succeeds Gabriel Leung, who is stepping down from his position as Chairman of the Board. Mr. Leung will remain on the Board, but his schedule demands inhibited his ability to continue as Chairman. Stoll's career spans more than 35 years in leadership positions in biotech, pharmaceutical and medical device companies including Bayer AG and Fresenius Medical Care - North America. In addition, he was the CEO of the Ohmeda global healthcare business unit of the BOC Group, plc. Prior to joining Delcath in 2012, Dr. Simpson served as the Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc., a wholly owned subsidiary of Eli Lilly and Company.

Two Companies To Bid For Delcath Systems

Two Nasdaq traded healthcare companies are interested for a merger with Delcath Systems, Inc. (NasdaqCM:DCTH). Companies approached Linkedto Partners for a merger or buyout. Linkedto Partners said, "We will get back in contact with the Delcath Board to pass on the two interested parties contact information. The Delcath Board has failed shareholders and the Delcath Management has also failed shareholders. We believe with these two other public companies' interest there are there at least three potential bids for the company on the table to consider as soon."

Linkedto Partners Re-Iterates Call For Delcath To Put Itself For Sale

Activist firm, Linkedto Partners, re-iterates call for Delcath Systems, Inc. (NasdaqCM:DCTH) to put itself for sale & cut excess compensation immediately. Linkedto Partners is pretty sure if the company is put up for sale, it will attract some major pharma companies interested in Europe and American sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $1.92 USD -0.06

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $12.35 USD -0.61
CTI BioPharma Corp $2.42 USD -0.005
Curis Inc $1.37 USD -0.045
Exact Sciences Corp $18.64 USD -0.74
Sirtex Medical Ltd A$22.30 AUD +0.33
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.2x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.